A detailed history of Bank Of America Corp transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Bank Of America Corp holds 189,398 shares of ABUS stock, worth $607,967. This represents 0.0% of its overall portfolio holdings.

Number of Shares
189,398
Previous 83,277 127.43%
Holding current value
$607,967
Previous $257,000 183.66%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $4.56 $331,097 - $483,911
106,121 Added 127.43%
189,398 $729,000
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $37,331 - $53,774
14,814 Added 21.64%
83,277 $257,000
Q1 2024

May 15, 2024

SELL
$2.26 - $2.92 $53,082 - $68,584
-23,488 Reduced 25.54%
68,463 $176,000
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $33,074 - $49,710
-19,571 Reduced 17.55%
91,951 $229,000
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $52,740 - $72,047
23,545 Added 26.76%
111,522 $256,000
Q1 2023

May 12, 2023

BUY
$2.23 - $3.1 $30,553 - $42,473
13,701 Added 18.45%
87,977 $266,000
Q4 2022

Feb 10, 2023

BUY
$1.91 - $2.85 $36,465 - $54,412
19,092 Added 34.6%
74,276 $173,000
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $31,448 - $48,176
16,728 Added 43.5%
55,184 $105,000
Q2 2022

Aug 12, 2022

SELL
$1.98 - $3.17 $18,427 - $29,503
-9,307 Reduced 19.49%
38,456 $104,000
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $1.6 Million - $2.62 Million
-659,334 Reduced 93.25%
47,763 $143,000
Q4 2021

Feb 08, 2022

BUY
$3.11 - $4.61 $281,492 - $417,260
90,512 Added 14.68%
707,097 $2.75 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $713,382 - $1.24 Million
269,201 Added 77.49%
616,585 $2.65 Million
Q2 2021

Sep 13, 2021

BUY
$2.5 - $3.51 $868,460 - $1.22 Million
347,384 New
347,384 $1.05 Million

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $481M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.